Tiragolumab may synergize with other immunotherapies to enhance antitumor immune responses. We report efficacy, safety, and biomarker findings from SKYSCRAPER-02C (NCT04665856), comparing tiragolumab plus atezolizumab plus carboplatin/etoposide (CE; experimental arm) with atezolizumab plus CE (control arm) in patients with untreated extensive-stage small-cell lung cancer (ES-SCLC) in China.
Journal of Thoracic Oncology (JTO) published a clinical update in Oncology on 05 Apr 2026.
The item focuses on SKYSCRAPER-02C: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab in Patients With Untreated Extensive-Stage Small Cell Lung Cancer in China.
Review the original article for the full source wording and details.